Current culture is still reliant on the work of Koch, Hesse and Pasteur from the 1860’s. Typical wait times for results are slow and inconclusive more than 80% of the time.

Synvichor introduces novel genomic host response-based diagnostics, developed through AI-driven discovery.

Synvichor combines proprietary biomarkers with established PCR testing techniques to translate the signalling that occurs when patients suffer joint pain.

Synvichor’s proprietary machine-learned interpretive algorithm rapidly differentiates between infectious and non-infectious joint inflammation with up to 96% positive and 99% negative predictive values.